Dyadic International (NASDAQ:DYAI) Posts Earnings Results, Beats Estimates By $0.06 EPS

Dyadic International (NASDAQ:DYAI) announced its quarterly earnings results on Tuesday. The biotechnology company reported ($0.01) earnings per share for the quarter, beating the consensus estimate of ($0.07) by $0.06, Zacks reports. The company had revenue of $1.96 million during the quarter, compared to analysts’ expectations of $1.05 million. Dyadic International had a negative return on equity of 140.01% and a negative net margin of 188.09%. During the same period in the previous year, the business earned ($0.06) earnings per share.

Dyadic International Stock Performance

NASDAQ DYAI opened at $1.12 on Thursday. The company’s 50 day simple moving average is $1.13 and its two-hundred day simple moving average is $1.42. The company has a debt-to-equity ratio of 1.72, a current ratio of 5.39 and a quick ratio of 5.39. Dyadic International has a 1 year low of $0.93 and a 1 year high of $2.67. The stock has a market capitalization of $33.02 million, a PE ratio of -4.87 and a beta of 0.72.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and set a $6.00 target price on shares of Dyadic International in a report on Thursday.

About Dyadic International

Dyadic International, Inc, a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health.